Literature DB >> 19118854

Risks associated with vaccinia virus in the laboratory.

Adam MacNeil1, Mary G Reynolds, Inger K Damon.   

Abstract

Vaccinia virus (VACV) is used commonly in research laboratories. Non-highly attenuated strains of VACV are potentially pathogenic in humans, and VACV vaccination and biosafety level 2 facilities and protocols are currently recommended for vaccinated laboratory workers in the United States who handle non-highly attenuated strains of the virus. Despite this, laboratory-related VACV exposures continue to occur and a number of recent instances of VACV infection in non-vaccinated laboratory workers have been documented. We provide a discussion of the usage and risks associated with VACV in laboratory research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118854     DOI: 10.1016/j.virol.2008.11.045

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.

Authors:  Agam K Rao; Brett W Petersen; Florence Whitehill; Jafar H Razeq; Stuart N Isaacs; Michael J Merchlinsky; Doug Campos-Outcalt; Rebecca L Morgan; Inger Damon; Pablo J Sánchez; Beth P Bell
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-06-03       Impact factor: 35.301

2.  Laboratory-acquired vaccinia virus infection in a recently immunized person--Massachusetts, 2013.

Authors:  Christopher H Hsu; Julien Farland; Thomas Winters; Julia Gunn; Donna Caron; Jennifer Evans; Lynda Osadebe; Leon Bethune; Andrea M McCollum; Nishi Patel; Kimberly Wilkins; Whitni Davidson; Brett Petersen; M Anita Barry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-01       Impact factor: 17.586

3.  Generation of an Attenuated Tiantan Vaccinia Virus Strain by Deletion of Multiple Genes.

Authors:  Yiquan Li; Yilong Zhu; Shuang Chen; Wenjie Li; Xunzhe Yin; Shanzhi Li; Pengpeng Xiao; Jicheng Han; Xiao Li; Lili Sun; Ningyi Jin
Journal:  Front Cell Infect Microbiol       Date:  2017-10-31       Impact factor: 5.293

4.  Outbreak of Vaccinia Virus Infection from Occupational Exposure, China, 2017.

Authors:  Bing Lu; Lun-Biao Cui; Min-Hua Gu; Chao Shi; Chuan-Wu Sun; Kang-Chen Zhao; Jun Bi; Zhong-Ming Tan; Xi-Ling Guo; Xiang Huo; Chang-Jun Bao
Journal:  Emerg Infect Dis       Date:  2019-06       Impact factor: 6.883

5.  Novel Treatment of a Vaccinia Virus Infection from an Occupational Needlestick - San Diego, California, 2019.

Authors:  Erin R Whitehouse; Agam K Rao; Yon C Yu; Patricia A Yu; Margaret Griffin; Susan Gorman; Kristen A Angel; Eric C McDonald; Anna Liza Manlutac; Marie A de Perio; Andrea M McCollum; Whitni Davidson; Kimberly Wilkins; Eddy Ortega; Panayampalli S Satheshkumar; Michael B Townsend; Marcia Isakari; Brett W Petersen
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-10-25       Impact factor: 17.586

6.  In Silico Repurposed Drugs against Monkeypox Virus.

Authors:  Hilbert Yuen In Lam; Jia Sheng Guan; Yuguang Mu
Journal:  Molecules       Date:  2022-08-18       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.